Clinical Testing News and Research

RSS

Miniature pacemakers aim to make heart procedures for infants less invasive, more efficient

At 2:15 p.m. C.T. on Sunday, Nov. 11, Rohan Kumthekar, M.D., a cardiology fellow working in Dr. Charles Berul's bioengineering lab at the Sheikh Zayed Institute for Pediatric Surgical Innovation, part of Children's National Health System, presents a prototype for a miniature pacemaker at the American Heart Association's Scientific Sessions 2018.

9 Nov 2018

Researchers examine immune responses to CRISPR-Cas9 gene editing system

The CRISPR-Cas9 gene editing system has been generating excitement within the field of gene therapy, inspiring hopes of molecular tools capable of treating genetic diseases.

30 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Researchers awarded grant to advance testing of experimental heroin vaccine

Researchers at the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research and SUNY Upstate Medical University in Syracuse, N.Y., have been awarded a grant to advance an experimental heroin vaccine through Phase I/IIa clinical trials to assess both its safety and its efficacy against a morphine challenge.

17 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

New approach for bone marrow transplant could make it safer and more effective for patients

Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

26 Sep 2018

Blood, sweat and workplace wellness: Where to draw the line on incentives

Workplace wellness programs that offer employees a financial carrot for undergoing health screenings, sticking to exercise regimens or improving their cholesterol levels have long been controversial.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

UK and European research collaborations receive vote of confidence by three major cancer charities

UK and European research collaborations in cancer research have received a vote of confidence by three major cancer charities, with an announcement today of approximately £30 million into six international projects.

20 Sep 2018

Barrow Institute initiates $50 million effort to seek cure for glioblastoma

Barrow Neurological Institute has initiated a $50 million effort, supported by the single largest research grant in the history of brain tumor research, to seek a cure for the deadliest form of brain cancer.

11 Sep 2018

Mimicking Human Brain Development Using Organoids

Dr. Paul Tesar from the Tesar Laboratory at Case Western University, Ohio, discusses the importance of organoids in biological research and the development of organoids which are capable of simulating the early stages of human myelin.

7 Sep 2018

Researchers test experimental cancer vaccine on mice with aggressive melanoma

An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumors, scientists reported recently in the Proceedings of the National Academy of Sciences.

7 Sep 2018

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.

31 Aug 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

New minimally-invasive surgical technique may be most significant development in dialysis

A new minimally-invasive surgical technique for dialysis patients may be the most significant development in dialysis access in the last 50 years, according to the surgeon who performed the first two cases in the United States.

28 Aug 2018